ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Acute and delayed full thickness macular holes in patients with intravitreal VEGF-inhibitors therapy.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLimited studies with big databases have investigated the frequency of full thickness macular holes as serious complication of intravitreal injections. To analyze the frequency and describe the impact on visual acuity of acute and delayed full thickness macular holes caused by intravitreal injection with VEGF-inhibitors.
methods3,316 patient files of patients who have been treated with intravitreal injections with VEGF-inhibitors during the period from August 2005 to December 2024 were screened for occurrence of full thickness macular holes. A total of 16 patients with full thickness macular holes under therapy with VEGF-inhibitors in our outpatient eye clinic were identified. For further analysis and comparison a separation into an acute and a delayed occurrence of full thickness macular holes was performed. Main outcome was the frequency of full thickness macular holes under VEGF-inhibitor therapy in a large consecutive single center cohort. Secondary endpoints were the visual acuity and structural OCT outcome after surgical treatment.
resultsBetween August 2005 and December 2024 78,694 VEGF-inhibitor intravitreal injections in 3,316 patients and 4,474 eyes were performed. During this time 7 acute cases and 9 delayed cases of full thickness macular holes occurred. The relative risk was 0.02% per eye and intravitreal injection. In relation to the average number of intravitreal injections per treated eye, the relative risk was 0.16% for acute full thickness macular holes, 0.20% for delayed full thickness macular holes and 0.36% overall during an intravitreal injection course. All but one of the 16 patients were treated with pars plana vitrectomy and peeling of the inner limiting membrane. Even with adequate surgical therapy, the acute full thickness macular hole group remained with a more severe visual acuity loss than the delayed full thickness macular hole group (0.06 (20/333) vs. 0.4 (20/50); p =.006).
conclusionEven with paying crucial attention to the correct way of intravitreal injection administration, especially an acute macular hole remains a rare but threatening event for visual acuity in patients under VEGF-inhibitor therapy. Surgical treatment should be advised. KEY MESSAGES: What is known The frequency of full thickness macular hole development in eyes undergoing intravitreal injections with VEGF-inhibitors is expected to be low, but not well observed. What is new In a monocentric consecutive series of 78,694 VEGF-inhibitor intravitreal injections the frequency of full thickness macular holes was 0.36% per eye for an average course Full thickness macular holes during intravitreal injection therapy with VEGF-inhibitors remain a rare adverse event with a higher risk compared to untreated eyes of the same age and a significant impact on visual function.
Indexed as
Identifiers
41037076What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.